Precigen, Inc.
PGEN
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.61
Price+5.42%
$0.34
1Y
Price
Market Cap
$2.357b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-16.9%
EBITDA Margin-34.1%
Net Profit Margin-189.6%
Free Cash Flow Margin-16.9%
EBITDA Margin-34.1%
Net Profit Margin-189.6%
Free Cash Flow MarginRevenue
$31.595m
+226.3%
1y CAGR+112.0%
3y CAGR+64.8%
5y CAGREarnings
-$204.418m
+18.4%
1y CAGR-37.2%
3y CAGR-137.6%
5y CAGREPS
-$1.28
+9.2%
1y CAGR-70.4%
3y CAGR-52.2%
5y CAGRBook Value
$20.235m
$138.627m
Assets$118.392m
Liabilities$98.250m
DebtDebt to Assets
70.9%
-0.5x
Debt to EBITDAFree Cash Flow
-$117.568m
-30.9%
1y CAGR-20.0%
3y CAGR-14.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company